VEGFA and colorectal adenocarcinoma: Targeted therapy employs small molecule-based drugs or monoclonal antibodies raised against abnormally expressed proteins that are crucial for colorectal adenocarcinoma and mCRC cell growth, including anti-epidermal growth factor receptor (EGFR) agents, e.g. panitumumab and cetuximab, in addition to anti-vascular endothelial growth factor (VEGF) agents, e.g. bevacizumab and aflibercept [5–7].